Synchron Announces Long-Term Safety Results from Fully Implanted Endovascular Brain-Computer Interface Stentrode™ for Severe Paralysis
Retrieved on:
Tuesday, March 29, 2022
Health, Medical Devices, General Health, Clinical Trials, Research, Science, Biotechnology, Skull, Blood, 2014 Australian federal budget, National Health, Death, Disability, ALS, Research, Paralysis, Doctor of Philosophy, Neuroprosthetics, Hypertension, CEO, BCI, Nervous system, Office, Technology, Medical Research Council, MS, Epilepsy, Brain, American Academy, Science, Movement, Motor cortex, MNP, University, FDA, Depression, Patient, Silicon, Medical device, Medical imaging, Stent-electrode recording array, MD, Beckman Coulter, THE STENTRODE™, SYNCHRON, INC.
Stentrode also stayed in place for all four patients and the blood vessel in which the device was implanted remained open.
Key Points:
- Stentrode also stayed in place for all four patients and the blood vessel in which the device was implanted remained open.
- Receiving the Stentrode implant allowed participants to use a computer to communicate by text and perform daily tasks such as online shopping and banking.
- Synchron is the only company to receive FDA approval to conduct clinical trials of a permanently implanted BCI.
- Synchron, a brain interface platform company, is a leader in the field of implantable neural interface technology.